UTILITY OF ATHEROGENIC INDEX OF PLASMA AS A CARDIOVASCULAR RISK FACTOR IN SUB-CLINICAL HYPOTHYROID PATIENTS

Authors

  • Saqibah Rehman Department of Chemical Pathology and Endocrinology, Armed Forces Institute of Pathology, Rawalpindi, Pakistan
  • Usman Munir Department of Chemical Pathology and Endocrinology, Armed Forces Institute of Pathology, Rawalpindi, Pakistan
  • Qaiser Alam Department of Chemical Pathology and Endocrinology, Armed Forces Institute of Pathology, Rawalpindi, Pakistan
  • Zujaja Hina Haroon Department of Chemical Pathology and Endocrinology, Armed Forces Institute of Pathology, Rawalpindi, Pakistan
  • Muhammad Younas Department of Chemical Pathology and Endocrinology, Armed Forces Institute of Pathology, Rawalpindi, Pakistan
  • Muhammad Anwar Department of Chemical Pathology and Endocrinology, Armed Forces Institute of Pathology, Rawalpindi, Pakistan

DOI:

https://doi.org/10.69656/pjp.v20i2.1631

Keywords:

AIP, Hypothyroidism, Cardiovascular, Subclinical, Cardiovascular Disease, T3, T4, TSH

Abstract

Background: Atherogenic index of plasma (AIP) is a reliable indicator of the likelihood of developing atherosclerosis and coronary heart disease. The objective of this study was to assess the AIP as a cardiovascular risk factor in subclinical hypothyroid patients, in predicting cardiovascular risk in patients of subclinical hypothyroidism. Methods: This prospective, cross-sectional study was conducted at a tertiary care hospital-based laboratory. Patients with Thyroid Stimulating Hormone (TSH) values between 4.5–10 IU/L and normal T4 were enrolled in the study. The participants were tested after fasting 8–10 hours and at least 3 days of fat-free diet for lipid profile analyzed on an automated chemistry analyzer. Data were analysed using SPSS-22. The odds ratio test was used to assess the risk of outcome keeping 1 as a positive measure to encounter outcome. Results: A total of 170 patients were enrolled in the study. Their mean age was 44.7±10.8 years. The AIP results indicated 118 (69.4%) as high risk, 41 (24.1%) as intermediate risk, and 11 (6.4%) as low risk (p<0.001). The assessment of outcome risk results indicated a positive association of exposure to outcome in TSH value of 6–7 mIU/L as OR 2.15 (CI: 1.81–4.13) while TSH value of 8–9 mIU/L as OR 1.08 (CI: 0.71–2.16). Conclusion: Sub-clinical hypothyroidism is associated with a higher risk of AIP especially with TSH levels of 4–8 mIU/L and age group of <50 years.

Pak J Physiol 2024;20(2):7-10

Downloads

Download data is not yet available.

References

Salih MA, Salih SF. Proprotein convertase subtilisin and kexin type 9 in sub clinical hypothyroidism as a risk factor for cardiovascular disease. J Pharm Negat Res 2022;13(3):994–9.

Lamichhane A, Bista P, Pokhrel S, Bolakhe K, Joshi G, Aryal S, et al. Assessment of cardiovascular disease risk in females with subclinical hypothyroidism. J Lipids 2023;2023:4440275.

Luboshitzky R, Aviv A, Herer P, Lavie L. Risk factors for cardiovascular disease in women with subclinical hypothyroidism. Thyroid 2002;12(5):421–5.

Simlai S, Kumar P, Mohapatra TK, Sharma P. Hypothyroidism induced lipid peroxidation and coronary hazard in Lucknow. J Evid Based Med Healthc 2020;7(49):2907–12.

Nanda N, Bobby Z, Hamide A. Association of thyroid stimulating hormone and coronary lipid risk factors with lipid peroxidation in hypothyroidism. Clin Chem Lab Med 2008;46(5):674–9.

Popa CD, Arts E, Fransen J, van Riel PL. Atherogenic index and high-density lipoprotein cholesterol as cardiovascular risk determinants in rheumatoid arthritis: the impact of therapy with biologicals. Mediators Inflamm 2012;2012:785946.

Chaulin AM, Grigorieva YV, Suvorova GN, Duplyakov DV. Methods for modeling hypothyroidism: classification and modeling principles. Mol Med 2021;19(4):19–26. [Article in Russian].

Luster M, Duntas LH, Wartofsky L, (Eds). The thyroid and its diseases. Cham, Switzerland: Springer; 2019.

Hussain A, Elmahdawi AM, Elzeraidi NE, Nouh F, Algathafi K. The effects of dyslipidemia in subclinical hypothyroidism. Cureus 2019;11(11):e6173.

Ejaz M, Kumar P, Thakur M, Bachani P, Naz S, Lal K. Comparison of lipid profile in patients with and without subclinical hypothyroidism. Cureus 2021;13(8):e17301.

Kanthe PS, Patil BS, Bagali S, Deshpande A, Shaikh GB, Aithala M. Atherogenic index as a predictor of cardiovascular risk among women with different grades of obesity. Int J Collab Res Intern Med Public Health 2012;4(10):1767–74.

Dobiasova M. AIP –atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice. Vnitr Lek 2006;52(1):64–71.

Nwagha UI, Ikekpeazu EJ, Ejezie FE, Neboh EE, Maduka IC. Atherogenic index of plasma as useful predictor of cardiovascular risk among postmenopausal women in Enugu, Nigeria. Afr Health Sci 2010;10(3):248–52.

Abid HA, Abid ZS, Abid SA. Atherogenic indices in clinical practice and biomedical research: a short review. Baghdad J Biochem Appl Biol Sci 2021;2(02):60–70.

Guo X, Ma L. Inflammation in coronary artery disease-clinical implications of novel HDL-cholesterol-related inflammatory parameters as predictors. Coron Artery Dis 2023;34(1):66–77.

Al-Tai WF, Jaffer EM, Ali ZA. Evaluating the utility of plasma Atherogenic Index among several atherogenic parameters in patients with chronic renal failure on maintenance hemodialysis. J Fac Med Baghdad 2012;54(3):259–62.

Vanderpump MP, Tunbridge WM. Epidemiology and prevention of clinical and subclinical hypothyroidism. Thyroid. 2002 Oct 1;12(10):839-47.

Niroumand S, Khajedaluee M, Khadem-Rezaiyan M, Abrishami M, Juya M, Khodaee G, Dadgarmoghaddam M. Atherogenic Index of Plasma (AIP): A marker of cardiovascular disease. Medical journal of the Islamic Republic of Iran. 2015;29:240.

James SR, Ray L, Ravichandran K, Nanda SK. High atherogenic index of plasma in subclinical hypothyroidism: Implications in assessment of cardiovascular disease risk. Indian Journal of Endocrinology and Metabolism. 2016 Sep 1;20(5):656-61.

Madhura NS, Shankar M, Narasimhappa S. Subclinical hypothyroidism (SH) and atherogenic index of plasma (AIP) in women: a case-control study from a tertiary Care Hospital in South India. Cureus. 2020 Sep 24;12(9).

Collet TH, Gussekloo J, Bauer DC, den Elzen WP, Cappola AR, Balmer P, et al. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med 2012;172(10):799–809.

Inoue K, Ritz B, Brent GA, Ebrahimi R, Rhee CM, Leung AM. Association of subclinical hypothyroidism and cardiovascular disease with mortality. JAMA network Open 2020;3(2):e1920745.

Downloads

Published

30-06-2024

How to Cite

1.
Rehman S, Munir MU, Khan MQA, Haroon ZH, Younas M, Anwar M. UTILITY OF ATHEROGENIC INDEX OF PLASMA AS A CARDIOVASCULAR RISK FACTOR IN SUB-CLINICAL HYPOTHYROID PATIENTS. Pak J Phsyiol [Internet]. 2024 Jun. 30 [cited 2024 Aug. 7];20(2):7-10. Available from: https://pjp.pps.org.pk/index.php/PJP/article/view/1631

Issue

Vol. 20 No. 2 (2024): Pakistan Journal of Physiology

Section

Original Article

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.

Pakistan Journal of Physiology, Pak J Physiol, PJP is FREE for research and academic purposes. It can be freely downloaded and stored, printed, presented, projected, cited and quoted with full reference of, and acknowledgement to the author(s) and the PJP. The contents are published with an international CC-BY-ND-4.0 License.